How Companion Diagnostics Guide Targeted Treatment Decisions

A companion diagnostic is a test that provides information needed to use a specific therapy safely and effectively. Typically, it identifies a biological marker, such as a gene variant, protein expression level or other measurable feature, that indicates whether a patient is likely to respond to a particular drug. The test and the therapy are developed together, and the test is often regulated as a medical device while the drug is regulated separately. Professionals who want to study this area in a structured way can look at the Micro Diploma: Companion Diagnostics Management, which covers how these linked products are planned and run.

The core principle is a relationship between a biomarker and a treatment response. Researchers first identify a marker that appears to predict benefit or risk from a drug, often by comparing outcomes in patients who have the marker with those who do not. Clinical studies then test whether using the marker to select patients improves results. The diagnostic must measure the marker reliably, which means defining analytical performance such as accuracy, precision and the range of samples it can handle. It must also show clinical validity, meaning the marker actually predicts the outcome it is meant to predict.

Management of these products depends on coordination between several functions. Drug developers, diagnostic developers, laboratories and clinicians must agree on the marker, the sample type, the testing method and the decision rule for treatment. Changes in one element, such as a new assay version or a different sample collection kit, can affect how results are interpreted, so version control and documented procedures are central to the framework.

Consider a production setting in which a manufacturer makes a test kit that will be sold alongside a targeted cancer drug. The operations team sets up a controlled process for producing the reagents, with incoming material checks, batch records and stability testing. Each lot is released only after it passes defined quality tests, and any deviation is investigated before the material is used. Because the test must perform the same way across every batch, the manufacturer tracks trends in control results and adjusts the process when performance begins to drift.

In the same setting, the company must also manage the link between the diagnostic and the drug. If a laboratory partner reports a lower-than-expected rate of valid results, the operations team reviews sample handling, shipping conditions and testing steps to find the cause. Supply planning matters as well, since patients cannot be started on the therapy until a valid result is available. Many organizations therefore set service levels for turnaround time and maintain procedures for handling samples that fail or are inconclusive.

Companion diagnostics raise real challenges. Biomarkers that work well in one population may perform poorly in another, and a marker identified in trial participants may not reflect the broader patient group. Tests also need to keep working as technology changes, which requires ongoing validation and clear rules for when a new version counts as a different product. Some observers argue that the regulatory pathway for linked drug and test approvals can be complex, and that timing mismatches between the two can delay patient access.

The main takeaway is that a companion diagnostic is only as useful as the system that produces, delivers and interprets it. Managing these products well means treating quality, documentation and cross-functional coordination as core parts of the work. As more therapies are designed around specific biomarkers, the management of companion diagnostics is likely to become a more central skill in healthcare operations.